Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: J Am Acad Dermatol. 2012 Jan 14;66(4):634–641. doi: 10.1016/j.jaad.2011.11.958

Table I.

Study Timeline

Baseline (Day 0)
 - Informed consent obtained and determined subject eligibility
 - Randomized (1:1) into treatment group (PDL + imiquimod 5% cream) or the placebo group (PDL + vehicle cream)
 - Photographs
 - Baseline measurements with chromameter
 - Treatment with PDL
 - Laser speckle imaging done prior to and after laser treatment
 - Study medication dispensed
Day 1
 - Subject starts treatment with study cream on a 3 times per week schedule
Day 14
 - Assess for adverse events
 - Study drug accountability
Day 28
 - Assess for adverse events
 - Study drug accountability
Day 42
 - Assess for adverse events
 - Study drug accountability
End of Study (Day 56)
 - Assess for adverse events
 - Photographs
 - Measurements with chromameter
 - Study drug accountability and collection